Patents by Inventor John C. Sidney

John C. Sidney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides of human Papilloma virus for use in human T cell response inducing compositions
    Patent number: 7364741
    Abstract: A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: April 29, 2008
    Assignee: Pharmexa Inc.
    Inventors: Wybe Martin Kast, Cornelis Joseph Maria Melief, Alessandro D. Sette, John C. Sidney
  • MAGE-1 c-terminal immunogenic peptides
    Patent number: 6464980
    Abstract: The complete nucleotide and amino acid sequences of the human MAGE-1 antigen are provided. Peptides from residues of the C-terminal are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against MAGE-1 antigens. The peptides are particularly useful in methods for stimulating the immune response of individuals against MAGE-1 antigens associated with melanomas.
    Type: Grant
    Filed: April 2, 1996
    Date of Patent: October 15, 2002
    Assignee: Epimmune Inc.
    Inventors: John D. Fikes, Brian D. Livingston, Alessandro D. Sette, John C. Sidney
  • DNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides
    Patent number: 5750395
    Abstract: The complete nucleotide and amino acid sequences of the human MAGE-1 antigen are provided. Peptides from residues of the C-terminal are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against MAGE-1 antigens. The peptides are particularly useful in methods for stimulating the immune response of individuals against MAGE-1 antigens associated with melanomas.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 12, 1998
    Assignee: Cytel Corporation
    Inventors: John D. Fikes, Brian D. Livingston, Alessandro D. Sette, John C. Sidney